HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analyst Ratings as of May 17, 2018

May 17, 2018 - By Michael Day

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Corporate Logo

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Ratings Coverage

Total analysts of 2 have positions in HTG Molecular Diagnostics (NASDAQ:HTGM) as follows: 2 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since December 27, 2017 according to StockzIntelligence Inc HTG Molecular Diagnostics has 10 analyst reports. On Wednesday, January 24 the firm has “Buy” rating by H.C. Wainwright given. In Friday, March 23 report Canaccord Genuity maintained the stock with “Buy” rating. On Friday, January 5 the firm has “Buy” rating given by H.C. Wainwright. On Monday, January 8 the firm has “Buy” rating by Canaccord Genuity given. The stock rating was maintained by H.C. Wainwright with “Buy” on Tuesday, May 8. On Friday, March 23 the firm earned “Buy” rating by H.C. Wainwright. On Tuesday, April 17 H.C. Wainwright maintained HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) rating. H.C. Wainwright has “Buy” rating and $700 target. The company rating was maintained by H.C. Wainwright on Thursday, February 1. On Friday, January 5 the firm has “Buy” rating by Canaccord Genuity given. On Wednesday, December 27 the firm has “Buy” rating given by H.C. Wainwright. Listed here are HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) PTs and latest ratings.

08/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
17/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
23/03/2018 Broker: Canaccord Genuity Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $7 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7.0000 Maintain
01/02/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
24/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
08/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $5.0 Maintain
05/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain
27/12/2017 Broker: H.C. Wainwright Rating: Buy New Target: $6.0 Maintain

Ticker’s shares touched $3.52 during the last trading session after 3.56% change.HTG Molecular Diagnostics, Inc. has volume of 207,215 shares. Since May 17, 2017 HTGM has declined 59.58% and is downtrending. HTGM underperformed the S&P 500 by 71.13%.

HTG Molecular Diagnostics, Inc. develops and markets services and products based on proprietary technology that facilitates the routine use of targeted molecular profiling.The company has $99.81 million market cap. The companyÂ’s products, HTG Edge and HTG EdgeSeq platforms include instrumentation , consumables comprising assay kits, and software analytics that automate sample processing and profiles various molecular targets from samples a fraction of the size required by prevailing technologies.Last it reported negative earnings. The Company’s platforms generate a molecular profiling library for detection using next-generation sequencing.

For more HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) news posted briefly go to: Nasdaq.com, Globenewswire.com, Nasdaq.com, Globenewswire.com or Globenewswire.com. The titles are as follows: “HTG Molecular Diagnostics to Feature Its HTG EdgeSeq Precision Immuno-Oncology Panel at Booth #4113 at the …” posted on May 10, 2018, “HTG Molecular Diagnostics to Announce First Quarter Financial Results and Host Conference Call on Thursday, May 10” on April 27, 2018, “HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic …” with a publish date: May 07, 2018, “HTG Molecular Diagnostics Reports First Quarter 2018 Results” and the last “New Research: Key Drivers of Growth for HTG Molecular Diagnostics, Impinj, XOMA, Stock Yards, TriCo Bancshares …” with publication date: May 02, 2018.

HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.